Lung Immune Profiling Reveals Distinct Severe Pneumonia Subtypes

Severe pneumonia often progresses to respiratory failure requiring intensive care and mechanical ventilation. Despite similar clinical presentations, outcomes vary widely, complicating decisions on anti-inflammatory or supportive therapies. The condition remains a major cause of infectious mortality and a common challenge in critical care units. To help address this challenge, researchers have now identified three biologically distinct subtypes of severe pneumonia that may enable more precise, patient-specific treatment.

Researchers at the University of Cambridge and Addenbrooke's Hospital, part of Cambridge University Hospitals NHS Foundation Trust, defined three “pneumotypes” of severe pneumonia. The team collected fluid from the lungs of patients admitted to intensive care with suspected severe pneumonia and profiled immune cells, inflammatory mediators, and gene activity. The analysis showed that these lung-compartment patterns aligned with recovery trajectories, while standard blood tests failed to distinguish them.

The most prevalent pneumotype accounted for almost half of cases and was marked by immune suppression, epithelial injury, and bleeding in the alveoli, with few inflammatory signals. A second pneumotype made up just under a quarter of cases and combined a balanced immune response with active tissue repair, correlating with faster recovery and the shortest ventilation times. The most dangerous pneumotype resembled classic pneumonia, with severe, persistent inflammation and a flood of immature immune cells, and was associated with prolonged mechanical ventilation; this group may be most likely to respond to anti-inflammatory therapies.

These findings challenge syndrome-based labels such as sepsis or acute respiratory distress syndrome by emphasizing lung biology that routine blood tests can miss. The researchers note that current assays are too complex for rapid use but aim to create a simplified stratification tool to guide individualized therapy and antibiotic stewardship. The work was published in Nature Communications on June 23, 2026. Pneumonia remains the leading infectious cause of death worldwide, and severe cases frequently require intensive care and mechanical ventilation.

“If we know which subtype of pneumonia an individual has, we can potentially tailor their treatment more precisely, boosting the immune response in some while calming harmful inflammation in others. This has the potential to help critically ill patients, reduce deaths from pneumonia, shorten ICU stays and cut unnecessary antibiotic use,” said Dr. Vilas Navapurkar from the John Farman Intensive Care Unit at Addenbrooke’s Hospital.

Related Links
University of Cambridge
Cambridge University Hospitals NHS Foundation Trust